A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients

• Status: Completed
• Trial end date: 2005-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if IDN-6556, when given orally, is safe and effective in patients with chronic hepatitis C virus infection.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Conatus Pharmaceuticals Inc.
• Collaborator: Idun Pharmaceuticals
• Treatments: Caspase Inhibitors

Criteria

Inclusion Criteria:

• Chronic hepatitis C infection

• Unsuccessful prior HCV treatment

• Liver impairment (either AST or ALT 1.5-10.0 x ULN)

• Alpha-fetoprotein <= 50 ng/mL

• Adequate hematologic parameters

Exclusion Criteria:

• Decompensated or severe liver disease

• Hepatocellular carcinoma

• HIV infection

• Co-infection with hepatitis B virus (HBV)

• Renal impairment

• Pancreatitis

• Use of illicit or drugs of abuse

• History of alcohol abuse

• Presence of clinically significant cardiac arrhythmias

• If female, pregnant or lactating